Reporting owner · CIK 0001366268
Kayyem Jon Faiz
SEC Form 4 history across 1 companies, 4 transactions and 4 filings.
DIRInhibrx Biosciences, Inc.
Open-market transaction mix100% buys3 buys · 0 sales
Available history · Jun 03, 2026 – Sep 23, 2026
Latest insider transactions
Form 4 filings from available history.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
INBXInhibrx Biosciences, Inc. | Kayyem Jon FaizDIR | P · buySEC filing ↗ | $500kView disclosure → | |
INBXInhibrx Biosciences, Inc. | Kayyem Jon FaizDIR | A · grantDerivative securityAmended filingSEC filing ↗ | $0View disclosure → | |
INBXInhibrx Biosciences, Inc. | Kayyem Jon FaizDIR | P · buySEC filing ↗ | $500kView disclosure → | |
INBXInhibrx Biosciences, Inc. | Kayyem Jon FaizDIR | P · buySEC filing ↗ | $567kView disclosure → |
Latest Form 4 facts
Quick context from source filings
Latest open-market transaction
buy at Inhibrx Biosciences, Inc. on Sep 23, 2026 valued at $500,000.
Review SEC filingLatest sale
No open-market insider sale is available.
Monthly open-market activity
Last 2 reported months · purchases and sales
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| Jun 2026 | 0 | 0 | $0.00 | $0.00 | $0.00 |
| Sep 2026 | 3 | 0 | $1,567,580.00 | $0.00 | $1,567,580.00 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Average P/S size$522.5K
Median P/S size$500K
Direct1
Indirect3
Sep 23, 2026buy
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Companies in the disclosed reporting history
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
No purchases currently have the price observations needed for a 90-day return. This may reflect incomplete price coverage or purchases that have not reached the return window.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
3 observations · Sep 8, 2026 – Sep 23, 2026. Window ends at the latest available report, not today.
Selected observation · Sep 23, 2026434,360 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Sep 8, 2026 | 424,360 | Sep 8, 2026 | View transaction |
| Sep 16, 2026 | 429,360 | Sep 17, 2026 | View transaction |
| Sep 23, 2026 | 434,360 | Sep 23, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Kayyem Jon Faiz Insider Activity FAQ
SEC Form 4 context
Who is Kayyem Jon Faiz?
Kayyem Jon Faiz is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001366268.
Which companies has Kayyem Jon Faiz reported transactions for?
Inhibrx Biosciences, Inc., BIODESIX INC
When was Kayyem Jon Faiz's latest insider buy?
buy at Inhibrx Biosciences, Inc. on Sep 23, 2026 valued at $500,000.
When was Kayyem Jon Faiz's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.